GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (BSP:REGN34) » Definitions » Cyclically Adjusted FCF per Share

Regeneron Pharmaceuticals (BSP:REGN34) Cyclically Adjusted FCF per Share : R$2.25 (As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Regeneron Pharmaceuticals Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Regeneron Pharmaceuticals's adjusted free cash flow per share for the three months ended in Sep. 2024 was R$0.833. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is R$2.25 for the trailing ten years ended in Sep. 2024.

During the past 12 months, Regeneron Pharmaceuticals's average Cyclically Adjusted FCF Growth Rate was 12.60% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 40.10% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 42.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Regeneron Pharmaceuticals was 88.60% per year. The lowest was -7.40% per year. And the median was 8.30% per year.

As of today (2025-01-18), Regeneron Pharmaceuticals's current stock price is R$71.68. Regeneron Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2024 was R$2.25. Regeneron Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is 31.86.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Regeneron Pharmaceuticals was 1182.80. The lowest was 27.56. And the median was 66.20.


Regeneron Pharmaceuticals Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Regeneron Pharmaceuticals's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regeneron Pharmaceuticals Cyclically Adjusted FCF per Share Chart

Regeneron Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.42 0.70 1.39 1.65 1.73

Regeneron Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.86 1.73 1.98 2.20 2.25

Competitive Comparison of Regeneron Pharmaceuticals's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Regeneron Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regeneron Pharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regeneron Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Regeneron Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.



Regeneron Pharmaceuticals Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Regeneron Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Sep. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=0.833/133.0289*133.0289
=0.833

Current CPI (Sep. 2024) = 133.0289.

Regeneron Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201412 0.031 99.070 0.042
201503 -0.099 99.621 -0.132
201506 0.008 100.684 0.011
201509 0.419 100.392 0.555
201512 0.058 99.792 0.077
201603 -0.032 100.470 -0.042
201606 0.128 101.688 0.167
201609 0.248 101.861 0.324
201612 0.116 101.863 0.151
201703 0.138 102.862 0.178
201706 -0.040 103.349 -0.051
201709 0.158 104.136 0.202
201712 0.218 104.011 0.279
201803 0.257 105.290 0.325
201806 0.155 106.317 0.194
201809 0.206 106.507 0.257
201812 0.363 105.998 0.456
201903 0.456 107.251 0.566
201906 0.053 108.070 0.065
201909 0.262 108.329 0.322
201912 0.388 108.420 0.476
202003 0.374 108.902 0.457
202006 0.597 108.767 0.730
202009 -0.322 109.815 -0.390
202012 0.818 109.897 0.990
202103 0.470 111.754 0.559
202106 0.362 114.631 0.420
202109 2.534 115.734 2.913
202112 1.843 117.630 2.084
202203 1.437 121.301 1.576
202206 0.303 125.017 0.322
202209 -0.341 125.227 -0.362
202212 1.125 125.222 1.195
202303 0.829 127.348 0.866
202306 0.631 128.729 0.652
202309 0.664 129.860 0.680
202312 0.557 129.419 0.573
202403 0.974 131.776 0.983
202406 0.111 132.554 0.111
202409 0.833 133.029 0.833

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Regeneron Pharmaceuticals  (BSP:REGN34) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Regeneron Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=71.68/2.25
=31.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Regeneron Pharmaceuticals was 1182.80. The lowest was 27.56. And the median was 66.20.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Regeneron Pharmaceuticals Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Regeneron Pharmaceuticals's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Regeneron Pharmaceuticals Business Description

Address
777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Regeneron Pharmaceuticals Headlines

No Headlines